• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>PML

PML

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. Genentech to Present New Data at AAN Reinforcing Efficacy and Safety of Newly FDA Approved OCREVUS (Ocrelizumab) in Two Types of Multiple Sclerosis

    Genentech to Present New Data at AAN Reinforcing Efficacy and Safety of Newly FDA Approved OCREVUS (Ocrelizumab) in Two Types of Multiple Sclerosis

  2. FDA Advisory Committee Unanimously Recommends Approval of Genentech’s Subcutaneous Rituximab for Certain Blood Cancers

    FDA Advisory Committee Unanimously Recommends Approval of Genentech’s Subcutaneous Rituximab for Certain Blood Cancers

  3. A Closer Look at CEF Duration Risk

    An examination of 10 CEFs with the highest duration risk.

  4. Year in Review: Municipal CEFs

    We take a look at 2012's municipal CEF performance, distribution cuts, mergers, and more.

©2017 Morningstar Advisor. All right reserved.